DNA Methylation Signature Testing

Epigenetic alterations are observed in many congenital disorders, particularly neurodevelopmental disorders. For variants in genes encoding or impacting epigenetic regulators and associated with the clinical findings, DNA methylation is assessed to guide interpretation of potential pathogenicity. This approach focuses on genes with well-established epigenetic signatures and for which the presence of a unique signature can indicate the presence of a pathogenic variant and thereby, reclassify a VUS.

Turnaround time is 4 weeks.

Who is this test for?

  • Patients for whom assessing DNA methylation would be useful to confirm the pathogenicity of a VUS 
  • Patients with a clinical presentation suggestive of a possible underlying epigenetic disorder
  • Research study samples
Alamya Health Logo

Advancing precision genomic medicine for all